What is Proton Therapy
Read our Covid-19 policy

Call Now For More Information

General Questions or
Schedule an Appointment


Current Patients


Physician Line


Read our Covid-19 policy

Randomized Clinical Trial for Prostate Cancer

Randomized Clinical Trial for Prostate Cancer

SCCA Proton Therapy Center is participating in a Phase III randomized clinical trial that will compare Proton Beam Therapy (PBT) to Intensity-Modulated Radiation Therapy (IMRT) for low or intermediate risk prostate cancer.

“We want to advance cancer treatment for all patients and be at the forefront of proving the value of new treatments and technologies,” says Jing Zeng, MD, Radiation Oncologist and Assistant Professor at the University of Washington Medical Center.

Though both of these radiation therapies have been used in the past to treat prostate cancer, this will be the first clinical trial designed to compare the effectiveness of PBT versus IMRT in treating prostate cancer and minimizing side effects.

Both types of radiation therapy will be given once a day for 5 days over the course of eight to nine weeks with an estimated enrollment of 400 patients. Radiation oncologists will evaluate the efficacy of PBT versus IMRT for 2 years following treatment, which will involve comparing the reduction in mean EPIC bowel scores for men with low or low-intermediate risk of prostate cancer.

As for secondary outcome measures, physicians will evaluate patient-reported outcomes, cost effectiveness of treatment method, biomarkers of prostate cancer behavior, and any bowel, urinary and erectile dysfunction. Long-term survival rates will also be assessed in addition to late effects of secondary tumors.

For more information on current proton therapy studies, please visit: https://www.sccaprotontherapy.com/medical-professionals/clinical-literature